Avantor Q2 2023 Earnings Report

Avantor's financial performance reflected a challenging biopharma market, with strategic actions taken to offset headwinds and invest in long-term growth.

Key Takeaways

Avantor reported a decrease in net sales by 8.7% to $1.74 billion, with a core organic decline of 6.5%. Net income was ($7.3) million, while adjusted EBITDA reached $343.0 million. The company's diluted GAAP EPS was ($0.01), and adjusted EPS was $0.28. Operating cash flow was $168.2 million, and free cash flow was $138.1 million.

Net sales decreased by 8.7% to $1.74 billion, with a core organic decline of 6.5%.

Adjusted EBITDA was $343.0 million with a margin of 19.7%.

Diluted GAAP EPS was ($0.01), and adjusted EPS was $0.28.

Operating cash flow was $168.2 million, and free cash flow was $138.1 million.

Total Revenue

$1.74B

Previous year: $1.91B